Market News & Trends
Intellia Therapeutics Demonstrates Sustained & Durable Genome Editing With CRISPR/Cas9 in 1-Year Animal Study
Intellia Therapeutics, Inc. recently presented the full 12-month data of its completed long-term mouse study, demonstrating robust and durable in vivo genome editing post single-dose,…
Ascendis Pharma Announces Dosing of Subjects in Phase 1 Trial
Ascendis Pharma A/S recently announced it has dosed subjects in a Phase 1 trial of TransCon PTH, a long-acting prodrug of parathyroid hormone (PTH) in…
American Heart Association's New Scientific Statement Deems the Corus CAD Test Valid & Useful for Clinicians Evaluating Obstructive CAD
CardioDx, Inc., a molecular diagnostics company specializing in cardiovascular genomics, recently announced today in a Scientific Statement by the American Heart Association, the Corus® CAD…
Q BioMed Announces Development Partnership With Sphaera Pharma
Q BioMed Inc. recently announced a partnership with Sphaera Pharma to develop a new and proprietary analog of QBM-001 for pediatric developmental nonverbal disorder. "The…
ValGenesis Announces Strategic Partnership With VTI Life Sciences
ValGenesis Inc. recently announced the strategic partnership with VTI Life Sciences (VTI). This partnership enables VTI to provide clients with validation services using the latest…
Cytokinetics Announces Dosing of First Patient in Phase 3 Clinical Trial, Triggers $10-Million Milestone Payment
Cytokinetics, Incorporated recently announced that the first patient has been dosed in Japan in GALACTIC-HF (Global Approach to Lowering Adverse Cardiac Outcomes Through Improving Contractility…
Ajinomoto Althea, Inc. Opens Manufacturing Suites in New High Potency & Antibody Drug Conjugate Commercial Facility
Ajinomoto Althea, Inc. recently announced it will soon open a GMP production suite in its newly constructed High Potency Products (HPP) commercial manufacturing facility located…
Aclaris Therapeutics Announces Phase 2 Clinical Trial Data
Aclaris Therapeutics, Inc. recently announced that results from a Phase 2 clinical trial evaluating two concentrations (40% and 32.5%) of its drug candidate A-101 for…
ERT Reduces eCOA Delivery Time for Vaccine Trials by 75%
ERT, a global data and technology company that minimizes uncertainty and risk in clinical trials, recently announced a technology platform that provides fast, regulatory compliant,…
Roivant Sciences Launches Datavant to Improve Clinical Trials With Artificial Intelligence
Roivant Sciences recently announced the launch of Datavant, a new company focused on employing artificial intelligence to improve the clinical trial process. Datavant will be…
Catalent to Acquire Cook Pharmica for $950 Million
Catalent, Inc. (NYSE: CTLT), the leading global provider of advanced delivery technologies and development solutions for drugs, biologics, and consumer health products, recently announced it has…
Inspyr Therapeutics & Lewis and Clark Pharmaceuticals Complete Merger
Inspyr Therapeutics and Lewis and Clark Pharmaceuticals recently announced the successful completion of a merger to create an integrated biotechnology company. The newly combined company…
The Gene Editing Institute of Christiana Care’s Helen F. Graham Cancer Center & Research Institute Signs Agreement With ABS
To accelerate the development of next-generation cancer therapies, the Gene Editing Institute of the Helen F. Graham Cancer Center & Research Institute at Christiana Care Health…
Sandoz Proposed Biosimilar Accepted for Review by FDA
Sandoz, a Novartis Division, and the pioneer and global leader in biosimilars, announced today that the US FDA has accepted its Biologics License Application (BLA)…
Aptose Biosicences & CrystalGenomics Announce Issuance of US Patent
Aptose Biosciences Inc. recently announced that the United States Patent and Trademark Office has issued US Patent No. 9,758,508 titled 2,3-DIHYDRO-ISOINDOLE-1-ON DERIVATIVE AS BTK KINASE…
Immuno-Oncology Looks Set to Become Fifth Pillar of Cancer Treatment
Immuno-Oncology (IO) looks set to become the fifth pillar of cancer treatment alongside surgery, radiotherapy, chemotherapy, and other targeted treatments according to GlobalData, a recognized…
Halozyme Lands Monster R&D Deals Worth Over $2 Billion for Drug Delivery Technology
Bristol-Myers Squibb has signed a partnership deal with San Diego-based Halozyme Therapeutics to use Halozyme’s ENHANZE drug delivery technology to develop a new way to…
DFB Pharmaceuticals Forms NanOlogy & Soria for Clinical Development of Naked Nanoparticle Platform
Demand for new cancer drugs is enormous with public and private investment skyrocketing for new technologies. Immunotherapies have captured much of the attention in recent…
APAC Drug Delivery Devices Market to Reach $5.4 Billion in 2023
Drug delivery devices market in Asia Pacific (India, China, Japan, South Korea, Australia, New Zealand, and Taiwan) region is expected to grow at CAGR 3.9%,…
AMRI’s Global Analytical Services Introduces Comprehensive Forced Degradation Services
AMRI’s Global Analytical Services is pleased to launch a new comprehensive forced degradation service to meet the industry demand for supporting drug substance, product including…
